News

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
MPR1d
FDA Approves Self-Administration Option for Vyvgart Hytrulo
After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.
Fierce Pharma1d
Argenx stays on a roll with Vyvgart, gaining FDA nod for at-home prefilled syringe
Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...
Contract Pharma1d
FDA Approves argenx’s VYVGART Hytrulo Prefilled Syringe for Self-Injection
Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...
Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe
The U.S. Food and Drug Administration (FDA) has approved Dutch biotech argenx’s (NASDAQ:ARGX) (OTCPK:ARGNF) autoimmune ...
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster ...
Argenx announces FDA approval of Vyvgart self-injection option
Argenx (ARGX) announced that the U.S. Food and Drug Administration approved a new option for patients to self-inject VYVGART Hytrulo with a ...
Pharmabiz2d
argenx SE highlights VYVGART data setting new standard in efficacy and improved quality of life measures for patients with gMG and CIDP
Amsterdam, the Netherlands Thursday, April 10, 2025, 18:00 Hrs [IST] ...
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across ...
Takeda Canada says Health Canada expands marketing authorization for HyQvia
Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with ...
rarediseaseadvisor15d
Dynamometry Could Improve CIDP Testing and Treatment
They concluded that dynamometry “holds significant potential” to improve testing and treatment in patients with CIDP, thereby having a positive impact on patients’ quality of life. CIDP is a rare and ...